Algeria Advances Toward Pharmaceutical Sovereignty, Cementing Its Role as Rising Regional Power

Algeria Advances Toward Pharmaceutical Sovereignty, Cementing Its Role as Rising Regional Power

✍️ 𝓑𝔂: 𝓓𝓻. 𝓗𝓪𝓷𝓪 𝓢𝓪𝓪𝓭𝓪

What was once an ambitious objective has become a tangible reality. Official indicators show that approximately 83 percent of national pharmaceutical needs are now covered by local production — a figure expected to climb further as dozens of newly licensed projects come online in the coming years.

Institutional Reform and Industrial Expansion

This acceleration reflects high-level political commitment to pharmaceutical sovereignty. The establishment of the Ministry of Pharmaceutical Industry in 2020, alongside the creation of the National Agency for Pharmaceutical Products the same year, laid the foundations for a more rigorous and efficient regulatory architecture.

Today, Algeria counts 233 pharmaceutical production units and factories, with nearly 100 additional authorized projects under development. The national system includes more than 780 production lines manufacturing both conventional and complex medicines — a clear indication of technological upgrading and meaningful technology transfer. These figures position Algeria among the most significant pharmaceutical actors on the African continent.

Insulin and Oncology Drugs: A Qualitative Leap

One of the most emblematic breakthroughs has been the full domestic manufacturing of insulin pens, now produced at 100 percent locally. This milestone places Algeria in a leading position in Africa and the Arab world.

Equally significant is the production of approximately 54 types of oncology medicines out of nearly 200 treatments registered in the national anti-cancer formulary. Beyond reducing import bills, this expansion has directly improved patient access, shortened waiting periods, and eased pressure on costly overseas treatment programs — particularly for chronic and complex illnesses.

Reducing Overseas Treatment, Strengthening Equity

For years, treatment abroad remained an unavoidable option for many patients due to limited local availability of advanced therapies. The steady expansion of national production — particularly in oncology and insulin — alongside projects in innovative medicines and cell therapy, is gradually reshaping this equation.

Each medicine produced domestically represents a further step toward reducing outbound medical transfers, bringing care closer to citizens, and strengthening equity in access to treatment.

Research initiatives in biotechnology and vaccine production, as well as cell therapy partnerships with the state-owned pharmaceutical group Saïdal, open new horizons for medical innovation within Algeria itself, reducing reliance on external therapeutic solutions.

Toward International Recognition

In its bid to consolidate international confidence in Algerian pharmaceuticals, Algeria recently hosted a delegation of experts from the World Health Organization to evaluate its national regulatory system. The assessment forms part of efforts to attain Maturity Level 3 under the WHO Global Benchmarking Tool for regulatory systems.

The evaluation covered four key institutions: the Ministry of Health, the Ministry of Pharmaceutical Industry, the National Agency for Pharmaceutical Products, and the National Pharmacovigilance Center.

A comprehensive self-assessment generated more than 430 recommendations across nine core regulatory functions, including drug registration, pharmacovigilance, inspection, and clinical trials oversight. Authorities report that over 78 percent of certain recommendations have already been implemented, with continued work underway in preparation for formal evaluation.

Securing Maturity Level 3 would effectively serve as a “green passport” for Algerian medicines — strengthening international recognition, expanding export opportunities, and enhancing prospects for industrial partnerships.

The pharmaceutical transformation extends beyond public health. New projects are expected to generate high-value employment in research, development, and biotechnology, reinforcing Algeria’s knowledge economy and helping stem the outflow of skilled professionals.

As Algeria consolidates its industrial and regulatory capacities, it moves steadily closer to achieving pharmaceutical sovereignty — reinforcing its independent health decision-making and asserting itself as an emerging pharmaceutical power in Africa and the wider region.

— 𝐄𝐍𝐃 —

📡🌍 | 𝓐𝓫𝓸𝓾𝓽 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓜𝓮𝓭𝓲𝓪 𝓖𝓻𝓸𝓾𝓹 | 🌍📡
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
📰 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓲𝓼 𝓪 𝓽𝓻𝓪𝓲𝓵𝓫𝓵𝓪𝔃𝓮𝓻 𝓲𝓷 𝓐𝓵𝓰𝓮𝓻𝓲𝓪𝓷 𝓭𝓲𝓰𝓲𝓽𝓪𝓵 𝓳𝓸𝓾𝓻𝓷𝓪𝓵𝓲𝓼𝓶, 𝓭𝓮𝓵𝓲𝓿𝓮𝓻𝓲𝓷𝓰 𝓱𝓲𝓰𝓱-𝓺𝓾𝓪𝓵𝓲𝓽𝔂 𝓬𝓸𝓷𝓽𝓮𝓷𝓽 𝓲𝓷 𝓐𝓻𝓪𝓫𝓲𝓬, 𝓕𝓻𝓮𝓷𝓬𝓱, 𝓪𝓷𝓭 𝓔𝓷𝓰𝓵𝓲𝓼𝓱. 𝓦𝓲𝓽𝓱 𝓶𝓸𝓻𝓮 𝓽𝓱𝓪𝓷 📈 500,000 𝓭𝓪𝓲𝓵𝔂 𝓬𝓵𝓲𝓬𝓴𝓼, 𝓲𝓽 𝓻𝓪𝓷𝓴𝓼 𝓪𝓶𝓸𝓷𝓰 𝓽𝓱𝓮 𝓶𝓸𝓼𝓽 𝓲𝓷𝓯𝓵𝓾𝓮𝓷𝓽𝓲𝓪𝓵 𝓶𝓮𝓭𝓲𝓪 𝓹𝓵𝓪𝓽𝓯𝓸𝓻𝓶𝓼 𝓲𝓷 𝓽𝓱𝓮 𝓬𝓸𝓾𝓷𝓽𝓻𝔂.

🏆 𝓐𝔀𝓪𝓻𝓭𝓮𝓭 𝓽𝓱𝓮 𝓟𝓻𝓮𝓼𝓲𝓭𝓮𝓷𝓽 𝓸𝓯 𝓽𝓱𝓮 𝓡𝓮𝓹𝓾𝓫𝓵𝓲𝓬’𝓼 𝓟𝓻𝓲𝔃𝓮 𝓯𝓸𝓻 𝓟𝓻𝓸𝓯𝓮𝓼𝓼𝓲𝓸𝓷𝓪𝓵 𝓙𝓸𝓾𝓻𝓷𝓪𝓵𝓲𝓼𝓽 𝓲𝓷 𝓽𝓱𝓮 𝓔𝓵𝓮𝓬𝓽𝓻𝓸𝓷𝓲𝓬 𝓟𝓻𝓮𝓼𝓼 𝓬𝓪𝓽𝓮𝓰𝓸𝓻𝔂 (🗓 𝓞𝓬𝓽𝓸𝓫𝓮𝓻 22, 2022), 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓲𝓼 𝔀𝓲𝓭𝓮𝓵𝔂 𝓻𝓮𝓬𝓸𝓰𝓷𝓲𝔃𝓮𝓭 𝓯𝓸𝓻 𝓲𝓽𝓼 𝓮𝓭𝓲𝓽𝓸𝓻𝓲𝓪𝓵 𝓮𝔁𝓬𝓮𝓵𝓵𝓮𝓷𝓬𝓮 𝓪𝓷𝓭 𝓲𝓷𝓽𝓮𝓰𝓻𝓲𝓽𝔂.

📱 𝓜𝓪𝓼𝓼𝓲𝓿𝓮 𝓓𝓲𝓰𝓲𝓽𝓪𝓵 𝓡𝓮𝓪𝓬𝓱:
🔴 600,000+ 𝓨𝓸𝓾𝓣𝓾𝓫𝓮 𝓼𝓾𝓫𝓼𝓬𝓻𝓲𝓫𝓮𝓻𝓼
🔵 6 𝓶𝓲𝓵𝓵𝓲𝓸𝓷+ 𝓯𝓸𝓵𝓵𝓸𝔀𝓮𝓻𝓼 𝓪𝓬𝓻𝓸𝓼𝓼 𝓕𝓪𝓬𝓮𝓫𝓸𝓸𝓴 𝓹𝓪𝓰𝓮𝓼
📸 70,000+ 𝓘𝓷𝓼𝓽𝓪𝓰𝓻𝓪𝓶 𝓯𝓸𝓵𝓵𝓸𝔀𝓮𝓻𝓼

🎥 𝓞𝓹𝓮𝓻𝓪𝓽𝓲𝓷𝓰 𝓯𝓻𝓸𝓶 𝓼𝓽𝓪𝓽𝓮-𝓸𝓯-𝓽𝓱𝓮-𝓪𝓻𝓽 𝓼𝓽𝓾𝓭𝓲𝓸𝓼, 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓫𝓻𝓸𝓪𝓭𝓬𝓪𝓼𝓽𝓼 𝓻𝓲𝓬𝓱 𝓪𝓷𝓭 𝓭𝓲𝓿𝓮𝓻𝓼𝓮 𝓹𝓻𝓸𝓰𝓻𝓪𝓶𝓶𝓲𝓷𝓰, 𝓲𝓷𝓬𝓵𝓾𝓭𝓲𝓷𝓰:
🗞 𝓝𝓮𝔀𝓼 | ⚽ 𝓢𝓹𝓸𝓻𝓽𝓼 | 🎭 𝓔𝓷𝓽𝓮𝓻𝓽𝓪𝓲𝓷𝓶𝓮𝓷𝓽 | 🕌 𝓡𝓮𝓵𝓲𝓰𝓲𝓸𝓷 | 🎨 𝓒𝓾𝓵𝓽𝓾𝓻𝓮

🗣️ 𝓕𝓮𝓪𝓽𝓾𝓻𝓲𝓷𝓰 𝓲𝓷𝓽𝓮𝓻𝓪𝓬𝓽𝓲𝓿𝓮 𝓽𝓪𝓵𝓴 𝓼𝓱𝓸𝔀𝓼 𝓪𝓷𝓭 𝓮𝔁𝓬𝓵𝓾𝓼𝓲𝓿𝓮 𝓲𝓷𝓽𝓮𝓻𝓿𝓲𝓮𝔀𝓼 𝔀𝓲𝓽𝓱 𝓹𝓻𝓸𝓶𝓲𝓷𝓮𝓷𝓽 𝓯𝓲𝓰𝓾𝓻𝓮𝓼 𝓯𝓻𝓸𝓶 𝓹𝓸𝓵𝓲𝓽𝓲𝓬𝓼, 𝓫𝓾𝓼𝓲𝓷𝓮𝓼𝓼, 𝓪𝓻𝓽𝓼, 𝓪𝓷𝓭 𝓶𝓸𝓻𝓮, 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓼𝓮𝓻𝓿𝓮𝓼 𝓪𝓼 𝓪 𝓴𝓮𝔂 𝓹𝓵𝓪𝓽𝓯𝓸𝓻𝓶 𝓯𝓸𝓻 𝓹𝓾𝓫𝓵𝓲𝓬 𝓭𝓲𝓼𝓬𝓸𝓾𝓻𝓼𝓮 𝓪𝓷𝓭 𝓬𝓲𝓿𝓲𝓬 𝓮𝓷𝓰𝓪𝓰𝓮𝓶𝓮𝓷𝓽.

📰 𝓘𝓽𝓼 𝓹𝓻𝓲𝓷𝓽 𝓼𝓹𝓸𝓻𝓽𝓼 𝓭𝓪𝓲𝓵𝔂, “𝓓𝔃𝓪𝓲𝓻 𝓢𝓹𝓸𝓻𝓽,” 𝓮𝓷𝓳𝓸𝔂𝓼 𝓸𝓿𝓮𝓻 50,000 𝓭𝓪𝓲𝓵𝔂 𝓭𝓸𝔀𝓷𝓵𝓸𝓪𝓭𝓼 𝓿𝓲𝓪 𝓽𝓱𝓮 𝓸𝓯𝓯𝓲𝓬𝓲𝓪𝓵 𝔀𝓮𝓫𝓼𝓲𝓽𝓮—𝓯𝓾𝓻𝓽𝓱𝓮𝓻 𝓬𝓮𝓶𝓮𝓷𝓽𝓲𝓷𝓰 𝓽𝓱𝓮 𝓹𝓵𝓪𝓽𝓯𝓸𝓻𝓶’𝓼 𝓶𝓾𝓵𝓽𝓲𝓶𝓮𝓭𝓲𝓪 𝓵𝓮𝓪𝓭𝓮𝓻𝓼𝓱𝓲𝓹.

🎖️ 𝓗𝓸𝓷𝓸𝓻𝓮𝓭 𝔀𝓲𝓽𝓱 𝓽𝓱𝓮 𝓜𝓮𝓭𝓲𝓪 𝓛𝓮𝓪𝓭𝓮𝓻𝓼𝓱𝓲𝓹 𝓐𝔀𝓪𝓻𝓭 𝓫𝔂 𝓽𝓱𝓮 𝓯𝓸𝓻𝓶𝓮𝓻 𝓜𝓲𝓷𝓲𝓼𝓽𝓮𝓻 𝓸𝓯 𝓒𝓸𝓶𝓶𝓾𝓷𝓲𝓬𝓪𝓽𝓲𝓸𝓷, 𝓜𝓸𝓱𝓪𝓶𝓮𝓭 𝓛𝓪â𝓰𝓪𝓫, 𝓪𝓷𝓭 𝓬𝓮𝓵𝓮𝓫𝓻𝓪𝓽𝓮𝓭 𝓪𝓽 𝓽𝓱𝓮 𝓗𝓲𝓵𝓪𝓵𝓼 𝓸𝓯 𝓽𝓱𝓮 𝓣𝓮𝓵𝓮𝓿𝓲𝓼𝓲𝓸𝓷 𝓪𝔀𝓪𝓻𝓭𝓼, 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓬𝓸𝓷𝓽𝓲𝓷𝓾𝓮𝓼 𝓽𝓸 𝓵𝓮𝓪𝓭 𝔀𝓲𝓽𝓱 𝓲𝓷𝓷𝓸𝓿𝓪𝓽𝓲𝓸𝓷, 𝓲𝓷𝓯𝓵𝓾𝓮𝓷𝓬𝓮, 𝓪𝓷𝓭 𝓲𝓶𝓹𝓪𝓬𝓽.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
🌐 𝓢𝓽𝓪𝔂 𝓒𝓸𝓷𝓷𝓮𝓬𝓽𝓮𝓭:
🔗 𝓦𝓮𝓫𝓼𝓲𝓽𝓮: www.dzair-tube.dz
🔗 𝓔𝓷𝓰𝓵𝓲𝓼𝓱: www.dzair-tube.dz/en
📲 𝓕𝓸𝓵𝓵𝓸𝔀 𝓾𝓼 𝓸𝓷 𝓕𝓪𝓬𝓮𝓫𝓸𝓸𝓴 | 𝓘𝓷𝓼𝓽𝓪𝓰𝓻𝓪𝓶 | 𝓨𝓸𝓾𝓣𝓾𝓫𝓮
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━